Literature DB >> 10226586

Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines.

A E al Moustafa1, M Alaoui-Jamali, J Paterson, M O'Connor-McCourt.   

Abstract

The receptors erbB-3 and erbB-4 are members of the type 1 tyrosine kinase receptor family which also comprises epidermal growth factor receptor (EGF-R) and erbB-2. ErbB-3 and erbB-4 receptors are known to bind a family of related proteins termed heregulins. In this study, we report differential expression of P185erbB-2, P160erbB-3 and P180erbB-4, and their ligand heregulin alpha, in normal bronchial epithelial, and non-small cell lung carcinoma (NSCLC) cell lines. Expression of P185erbB-2 and P160erbB-3 vary from very low to a high level in NSCLC cell lines and a low level in normal bronchial cells. In contrast, P180erbB-4 was detected only in NSCLC cell lines but not in normal bronchial cells. Heregulin alpha is expressed at intermediate levels in the normal and cancer cell lines studied. Immunoprecipitation, using antibodies to erbB-2, erbB-3 or erbB-4 receptors, coupled to phosphotyrosine Western blot analysis indicates that these three receptors are constitutively tyrosine phosphorylated in lung cancer cell lines, but only erbB-2 and erbB-3 are autophosphorylated in normal cells. These data suggest that constitutive activation of erbB-2, erbB-3 and erbB-4 receptors could be induced by heregulin alpha via an autocrine loop mechanism, and that the active forms of erbB-4 may cooperate with the other members of the EGF-receptor family in human lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226586

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  The interaction of the ErbB4 intracellular domain p80 with α-enolase in the nuclei is associated with the inhibition of the neuregulin1-dependent cell proliferation.

Authors:  Satomi Yamada; Masaki Marutsuka; Miyabi Inoue; Jidong Zhang; Shin-Ichi Abe; Ken-Ichi Ishibashi; Naoto Yamaguchi; Ko Eto
Journal:  Int J Biochem Mol Biol       Date:  2014-05-15

Review 3.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.

Authors:  Mark R Frey; Valda C Hilliard; Matthew T Mullane; D Brent Polk
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

5.  Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients.

Authors:  Mirza Masroor; Jamsheed Javid; Rashid Mir; Prasant Y; Imtiyaz A; Mariyam Z; Anant Mohan; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2015-08-09

Review 6.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

7.  Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

Authors:  Jeanne Mendell; Daniel J Freeman; Wenqin Feng; Thore Hettmann; Matthias Schneider; Sabine Blum; Jens Ruhe; Johannes Bange; Kenji Nakamaru; Shuquan Chen; Zenta Tsuchihashi; Joachim von Pawel; Catherine Copigneaux; Robert A Beckman
Journal:  EBioMedicine       Date:  2015-02-12       Impact factor: 8.143

8.  Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.

Authors:  Jessica Kristof; Kellen Sakrison; Xiaoping Jin; Kenji Nakamaru; Matthias Schneider; Robert A Beckman; Daniel Freeman; Cindy Spittle; Wenqin Feng
Journal:  Biomark Insights       Date:  2017-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.